Prince of Wales Hospital

First Use of the Galaxy System™ in Asia for Next Generation Robotic Bronchoscopy Conducted at Prince of Wales Hospital in Hong Kong

Retrieved on: 
Tuesday, December 5, 2023
Galaxy, Quality of life, Fluoroscopy, Physician, Biopsy, Prince, FDA, Lung cancer, MD, Doctor of Philosophy, SAN, Clinical trial, Prince of Wales Hospital, Patient, Diagnosis, Medical device

The Galaxy System allows physicians to confidently navigate to and biopsy lung nodules as part of a more effective and efficient bronchoscopy procedure.

Key Points: 
  • The Galaxy System allows physicians to confidently navigate to and biopsy lung nodules as part of a more effective and efficient bronchoscopy procedure.
  • The procedure marks the beginning of the first clinical trial of the robotic bronchoscopy system in Asia.
  • “We are excited to be the first site in Asia to trial this exciting new technology,” said Calvin Ng, MD.
  • The Hong Kong trial will focus on further validating the system’s TiLT+ Technology, its center-strike accuracy and overall diagnostic yield.

Cornerstone Robotics Shines Bright at ELSA2023, Latest Robotics Technology Captivates Attention

Retrieved on: 
Friday, October 13, 2023
Congress, Division, Endoscopy, Per-oral endoscopic myotomy, CSR, AI, Therapy, Robotics, Sofie (surgical robot), Medicine, Prince of Wales Hospital, C1000, Robot-assisted surgery, Growth, Speech, Tremor, ESD, Filtration, Surgeon, ELSA, Patient, MRC, Medical device, Dentistry

HONG KONG, Oct 13, 2023 - (ACN Newswire) - Cornerstone Robotics (CSR or the Company) is a leading company in Chinese surgical robotics industry.

Key Points: 
  • HONG KONG, Oct 13, 2023 - (ACN Newswire) - Cornerstone Robotics (CSR or the Company) is a leading company in Chinese surgical robotics industry.
  • Prof. Samuel Au delivered a speech on Surgical Robotics in the Future: Forging Accessibility in Robotic Surgery.
  • Founded in 2019, Cornerstone Robotics is committed to developing, producing, and distributing high-quality surgical robots.
  • The company has assembled an international team of surgical robotics experts and clinical professionals from a diverse range of disciplines.

Hong Kong to be gateway for CMR Surgical in APAC region

Retrieved on: 
Thursday, April 28, 2022
Urology, Surgeon, CMR, Prince of Wales Hospital, Infection, Biotechnology, CUHK Medical Centre, GMT, Patient, Gynaecology, Pain, Technology, Growth, Hong Kong Trade Development Council Trade Fairs, Hospital, Adoption, GHK, Gleneagles Hospital, General surgery, CMR Surgical, Colorectal surgery, Risk, Tutoring, Dentistry, Far East, Health care

CMR Surgical the global surgical robotics business has today announced the introduction of the Versius Surgical Robotic System in Hong Kong at CUHK Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK).

Key Points: 
  • CMR Surgical the global surgical robotics business has today announced the introduction of the Versius Surgical Robotic System in Hong Kong at CUHK Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK).
  • Hong Kong will be our springboard to the rest of APAC as we prepare for further developments in the region in due course and continue to set CMR Surgical on the global stage.
  • Dr Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council commented: Hong Kong is a leader in embracing innovation and technology, including in Healthcare.
  • It is great to see Versius standing out in Hong Kong and offering world leading surgeons a very different surgical robotic option.

Hong Kong to be gateway for CMR Surgical in APAC region

Retrieved on: 
Thursday, April 28, 2022
Urology, Surgeon, CMR, Prince of Wales Hospital, Infection, Biotechnology, GMT, Patient, Gynaecology, Pain, Technology, Growth, Hong Kong Trade Development Council Trade Fairs, Hospital, Adoption, GHK, Gleneagles Hospital, General surgery, CMR Surgical, CUHK Medical Centre, Colorectal surgery, Risk, Tutoring, Dentistry, Chinese University of Hong Kong, Far East, Health care

CMR Surgical the global surgical robotics business has today announced the introduction of the Versius Surgical Robotic System in Hong Kong at Chinese University of Hong Kong Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK).

Key Points: 
  • CMR Surgical the global surgical robotics business has today announced the introduction of the Versius Surgical Robotic System in Hong Kong at Chinese University of Hong Kong Medical Centre (CUHKMC) and Gleneagles Hospital Hong Kong (GHK).
  • Hong Kong will be our springboard to the rest of Asia as we prepare for further developments in the APAC region in due course and continue to set CMR Surgical on the global stage.
  • Dr Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council commented: Hong Kong is a leader in embracing innovation and technology, including in Healthcare.
  • We are delighted to be partnering with leading hospitals, Chinese University of Hong Kong Medical Centre and Gleneagles Hospital Hong Kong, to expand the benefits of robotic keyhole surgery.

Alucent Biomedical Announces First Patient Enrolled in First In Human Natural Vascular Scaffolding Clinical Trial

Retrieved on: 
Tuesday, April 12, 2022
Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Prince of Wales Hospital, Doppler ultrasonography, Flinders Medical Centre, Royal Perth Hospital, Angioplasty, Peripheral artery disease, Freedom, Patient, Technology, PAD, The Alfred Hospital, Safety, Quality of life, Vascular disease, Medical device

announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology .

Key Points: 
  • announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology .
  • The first patient in the ACTIVATE II study was enrolled by Dr. Chris Delaney at Flinders Medical Centre in Adelaide.
  • Alucent Biomedical is a privately held company dedicated to developing and commercializing its breakthrough Natural Vascular Scaffolding (AlucentNVS) technology for the treatment of vascular disease.
  • Alucent Biomedical was founded by the Avera Research Institute, part of the multistate Avera Health System, in 2017.